Investment Thesis
Hoth Therapeutics exhibits severe fundamental deterioration with net income declining 52.3% YoY to -$12.5M despite $1.2B in revenue, indicating severe profitability challenges. The company is burning $9.8M in operating cash annually against only $6.2M in cash reserves, creating critical liquidity pressure with less than 1 year of runway. Negative returns (ROE -202.7%, ROA -164%) and worsening trends suggest fundamental business model distress with no clear path to profitability.
Strengths
- Zero long-term debt provides balance sheet flexibility
- Current ratio of 4.72x indicates strong immediate liquidity position
- Minimal capital expenditure requirements suggest asset-light operations
Risks
- Severe cash burn of $9.8M annually against $6.2M cash reserves creates critical runway crisis
- Net income deteriorating 52.3% YoY signals accelerating fundamental weakness
- Massive negative returns on equity (-202.7%) and assets (-164%) indicate value destruction
- Revenue-to-profitability disconnect suggests accounting anomalies or non-recurring items masking core business weakness
- No insider activity in 90 days may reflect lack of confidence in recovery
Key Metrics to Watch
- Cash burn rate trend and remaining cash runway
- Operating cash flow sustainability and path to cash flow breakeven
- Revenue quality and recurring vs. non-recurring revenue composition
- Quarterly profitability trajectory and gross margin expansion
Financial Metrics
Revenue
1.2B
Net Income
-12.5M
EPS (Diluted)
$-0.90
Free Cash Flow
-9.8M
Total Assets
7.6M
Cash
6.2M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-1.0%
Net Margin
-1.0%
ROE
-202.7%
ROA
-164.0%
FCF Margin
-0.8%
Balance Sheet & Liquidity
Current Ratio
4.72x
Quick Ratio
4.72x
Debt/Equity
0.00x
Debt/Assets
19.1%
Interest Coverage
-85.84x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-11T07:03:21.877794 |
Data as of: 2025-12-31 |
Powered by Claude AI